Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW.

Cancer Cell. 2012 Nov 13;22(5):656-67. doi: 10.1016/j.ccr.2012.08.027.

2.

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.

Fei F, Stoddart S, Müschen M, Kim YM, Groffen J, Heisterkamp N.

Leukemia. 2010 Apr;24(4):813-20. doi: 10.1038/leu.2009.302. Epub 2010 Jan 28.

3.

ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.

Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ.

Leuk Res. 2011 Oct;35(10):1390-4. doi: 10.1016/j.leukres.2011.06.021. Epub 2011 Aug 2.

4.

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.

Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R.

Mol Cancer Ther. 2007 Apr;6(4):1400-5.

6.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, Wlodarska I, Vandenberghe P, Hagemeijer A, Marynen P, Cools J.

Blood. 2005 Jun 15;105(12):4849-52. Epub 2005 Feb 15.

7.

Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).

Krause S, Pfeiffer C, Strube S, Alsadeq A, Fedders H, Vokuhl C, Loges S, Waizenegger J, Ben-Batalla I, Cario G, Möricke A, Stanulla M, Schrappe M, Schewe DM.

Blood. 2015 Jan 29;125(5):820-30. doi: 10.1182/blood-2014-06-583062. Epub 2014 Nov 26.

8.

Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.

Mpakou VE, Kontsioti F, Papageorgiou S, Spathis A, Kottaridi C, Girkas K, Karakitsos P, Dimitriadis G, Dervenoulas I, Pappa V.

Leuk Res. 2013 Feb;37(2):175-82. doi: 10.1016/j.leukres.2012.10.011. Epub 2012 Nov 10.

PMID:
23149070
9.

In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.

Glover JM, Loriaux M, Tyner JW, Druker BJ, Chang BH.

Pediatr Blood Cancer. 2012 Sep;59(3):576-9. doi: 10.1002/pbc.23383. Epub 2011 Oct 28.

10.

ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.

Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps TJ.

Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):793-8. doi: 10.1073/pnas.1308374111. Epub 2013 Dec 30.

11.

Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Müschen M.

Blood. 2015 Jun 11;125(24):3688-93. doi: 10.1182/blood-2015-01-567842. Epub 2015 Apr 15. Review.

12.

Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.

Lin YC, Wu MH, Wei TT, Chuang SH, Chen KF, Cheng AL, Chen CC.

Neoplasia. 2012 Jun;14(6):463-75.

13.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
14.

Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.

Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R.

Cancer Biol Ther. 2012 Nov;13(13):1244-54. doi: 10.4161/cbt.21460. Epub 2012 Aug 16.

15.

Detection of orphan receptor tyrosine kinase (ROR-1) expression in Egyptian pediatric acute lymphoblastic leukemia.

Shaheen I, Ibrahim N.

Fetal Pediatr Pathol. 2012 Jun;31(3):113-9. doi: 10.3109/15513815.2012.656825. Epub 2012 Feb 27.

PMID:
22369092
16.

NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.

Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, Arima C, Kato S, Tomida S, Suzuki M, Osada H, Takahashi T.

Cancer Cell. 2012 Mar 20;21(3):348-61. doi: 10.1016/j.ccr.2012.02.008.

17.

BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.

Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Müschen M.

Oncogene. 2006 Feb 16;25(7):1118-24.

PMID:
16205638
18.

The targeting of human and mouse B lymphocytes by dasatinib.

Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY.

Exp Hematol. 2015 May;43(5):352-363.e4. doi: 10.1016/j.exphem.2015.01.008. Epub 2015 Jan 29.

PMID:
25641047
19.

ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.

Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ.

PLoS One. 2012;7(3):e31127. doi: 10.1371/journal.pone.0031127. Epub 2012 Mar 5.

20.

Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.

Ren M, Qin H, Ren R, Tidwell J, Cowell JK.

Cancer Res. 2011 Dec 1;71(23):7312-22. doi: 10.1158/0008-5472.CAN-11-1109. Epub 2011 Sep 21.

Supplemental Content

Support Center